Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasms

abstract

  • 5FU does not substantially affect the metabolism of CPT-11 to its active metabolite, SN-38. The combination of CPT-11125 mg/m2, 5FU 500 mg/m2, and leucovorin 20 mg/m2 is feasible and tolerable on this schedule.

publication date

  • November 14, 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8918493

Additional Document Info

start page

  • 2959

end page

  • 67

volume

  • 14

number

  • 11